Steer J H, Vuong Q, Joyce D A
Department of Pharmacology, University of Western Australia, Nedlands.
Br J Clin Pharmacol. 1997 Apr;43(4):383-9. doi: 10.1046/j.1365-2125.1997.00586.x.
Glucocorticoids suppress the release of tumour necrosis factor-alpha (TNF-alpha) by macrophages in vitro and cause monocytopaenia in vivo. These actions may contribute to anti-inflammatory and immunosuppressant effects. We therefore examined relationships between prednisolone concentration, suppression of monocyte TNF-alpha release, monocytopaenia and suppression of total cortisol concentration in healthy volunteers treated with a single dose (1.5 mg kg-1) of the glucocorticoid, prednisolone.
Monocyte numbers, total cortisol concentration and prednisolone concentration were measured in blood samples collected over 48 h after the dose. Plasma from these samples was also tested for its capacity to suppress lipopolysaccharide-induced TNF-alpha release from monocytes in autologous whole blood cultures.
At 4 h after the dose, monocyte numbers in peripheral blood had fallen to a mean of 18% of the pre-dose level whilst plasma total cortisol had fallen to 9% of the pre-dose concentration. Monocyte numbers recovered in concordance with elimination of prednisolone and there was a significant relative monocytosis at 24 h. The recovery of plasma cortisol was delayed in comparison, with cortisol remaining significantly suppressed at 24 h. Plasma samples taken at 2 h after the dose (corresponding to peak plasma prednisolone concentration) suppressed the lipopolysaccharide-stimulated production of TNF-alpha by autologous blood monocytes to 27% of pre-dose control. Plasma collected at intervals over the 48 h from dosing also suppressed monocyte TNF-alpha release in relation to the prednisolone concentration therein. Suppression was largely reversed by the glucocorticoid antagonist, mifepristone. A similar relationship between prednisolone concentration and TNF-alpha suppression was observed when prednisolone was added to blood samples collected from the volunteers when they were drug-free.
Blood concentration of prednisolone achieved after a dose of 1.5 mg kg-1 are sufficient to suppress monocyte TNF-alpha release and cause a biphasic change in peripheral blood monocyte numbers. Suppression of TNF-alpha is principally a direct glucocorticoid effect, rather than a consequence of other prednisolone-induced changes to blood composition.
糖皮质激素在体外可抑制巨噬细胞释放肿瘤坏死因子-α(TNF-α),在体内可导致单核细胞减少。这些作用可能有助于其抗炎和免疫抑制效应。因此,我们研究了在健康志愿者单次服用(1.5 mg/kg)糖皮质激素泼尼松龙后,泼尼松龙浓度、单核细胞TNF-α释放的抑制、单核细胞减少与总皮质醇浓度抑制之间的关系。
在给药后48小时内采集的血样中测量单核细胞数量、总皮质醇浓度和泼尼松龙浓度。这些样本的血浆也在自体全血培养中测试其抑制脂多糖诱导的单核细胞释放TNF-α的能力。
给药后4小时,外周血单核细胞数量降至给药前水平的平均18%,而血浆总皮质醇降至给药前浓度的9%。单核细胞数量随着泼尼松龙的消除而恢复,在24小时出现明显的相对单核细胞增多。相比之下,血浆皮质醇的恢复延迟,在24小时时皮质醇仍被显著抑制。给药后2小时采集的血浆样本(对应血浆泼尼松龙浓度峰值)将脂多糖刺激的自体血单核细胞产生的TNF-α抑制至给药前对照的27%。给药后48小时内间隔采集的血浆也根据其中的泼尼松龙浓度抑制单核细胞TNF-α释放。这种抑制在很大程度上被糖皮质激素拮抗剂米非司酮逆转。当在志愿者无药时采集的血样中加入泼尼松龙时,观察到泼尼松龙浓度与TNF-α抑制之间存在类似关系。
1.5 mg/kg剂量的泼尼松龙达到的血药浓度足以抑制单核细胞TNF-α释放,并导致外周血单核细胞数量出现双相变化。TNF-α的抑制主要是糖皮质激素的直接作用,而非泼尼松龙诱导的血液成分其他变化的结果。